000141809 001__ 141809
000141809 005__ 20240229112527.0
000141809 0247_ $$2doi$$a10.1002/ijc.32029
000141809 0247_ $$2pmid$$apmid:30499236
000141809 0247_ $$2ISSN$$a0020-7136
000141809 0247_ $$2ISSN$$a1097-0215
000141809 0247_ $$2altmetric$$aaltmetric:52057757
000141809 037__ $$aDKFZ-2018-02077
000141809 041__ $$aeng
000141809 082__ $$a610
000141809 1001_ $$aKim, Sehee$$b0
000141809 245__ $$aA Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
000141809 260__ $$aBognor Regis$$bWiley-Liss$$c2019
000141809 3367_ $$2DRIVER$$aarticle
000141809 3367_ $$2DataCite$$aOutput Types/Journal article
000141809 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1554213757_30313
000141809 3367_ $$2BibTeX$$aARTICLE
000141809 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141809 3367_ $$00$$2EndNote$$aJournal Article
000141809 520__ $$aAs a follow-up to genome-wide association analysis of common variants associated with ovarian carcinoma (cancer), this study considers seven well-known ovarian cancer risk factors and their interactions with 28 genome-wide significant common genetic variants. The interaction analyses were based on data from 9,971 ovarian cancer cases and 15,566 controls from 17 case-control studies. Likelihood ratio and Wald tests for multiplicative interaction and for relative excess risk due to additive interaction were used. The top multiplicative interaction was noted between oral contraceptive pill (OCP) use (ever vs never) and rs13255292 (P-value = 3.48 x 10-4 ). Among women with the TT genotype for this variant, the odds ratio for OCP use was 0.53 (95% CI=0.46-0.60) compared to 0.71 (95%CI=0.66-0.77) for women with the CC genotype. When stratified by duration of OCP use, women with 1-5 years of OCP use exhibited differential protective benefit across genotypes. However, no interaction on either the multiplicative or additive scale was found to be statistically significant after multiple testing correction. The results suggest that OCP use may offer increased benefit for women who are carriers of the T allele in rs13255292. On the other hand, for women carrying the C allele in this variant, longer (5+ years) use of OCP may reduce the impact of carrying the risk allele of this SNP. Replication of this finding is needed. The study presents a comprehensive analytic framework for conducting gene-environment analysis in ovarian cancer. This article is protected by copyright. All rights reserved.
000141809 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141809 588__ $$aDataset connected to CrossRef, PubMed,
000141809 7001_ $$aWang, Miao$$b1
000141809 7001_ $$aTyrer, Jonathan P$$b2
000141809 7001_ $$aJensen, Allan$$b3
000141809 7001_ $$aWiensch, Ashley$$b4
000141809 7001_ $$aLiu, Gang$$b5
000141809 7001_ $$aLee, Alice W$$b6
000141809 7001_ $$aNess, Roberta B$$b7
000141809 7001_ $$00000-0002-3659-1514$$aSalvatore, Maxwell$$b8
000141809 7001_ $$aTworoger, Shelley S$$b9
000141809 7001_ $$aWhittemore, Alice S$$b10
000141809 7001_ $$00000-0002-9603-0110$$aAnton-Culver, Hoda$$b11
000141809 7001_ $$aSieh, Weiva$$b12
000141809 7001_ $$aOlson, Sara H$$b13
000141809 7001_ $$aBerchuck, Andrew$$b14
000141809 7001_ $$00000-0002-9094-8326$$aGoode, Ellen L$$b15
000141809 7001_ $$aGoodman, Marc T$$b16
000141809 7001_ $$aDoherty, Jennifer Anne$$b17
000141809 7001_ $$aChenevix-Trench, Georgia$$b18
000141809 7001_ $$aRossing, Mary Anne$$b19
000141809 7001_ $$aWebb, Penelope M$$b20
000141809 7001_ $$aGiles, Graham G$$b21
000141809 7001_ $$aTerry, Kathryn L$$b22
000141809 7001_ $$aZiogas, Argyrios$$b23
000141809 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b24$$udkfz
000141809 7001_ $$aMenon, Usha$$b25
000141809 7001_ $$aGayther, Simon A$$b26
000141809 7001_ $$00000-0003-0546-902X$$aWu, Anna H$$b27
000141809 7001_ $$aSong, Honglin$$b28
000141809 7001_ $$aBrooks-Wilson, Angela$$b29
000141809 7001_ $$aBandera, Elisa V$$b30
000141809 7001_ $$aCook, Linda S$$b31
000141809 7001_ $$00000-0002-8024-3066$$aCramer, Daniel W$$b32
000141809 7001_ $$aMilne, Roger L$$b33
000141809 7001_ $$aWinham, Stacey J$$b34
000141809 7001_ $$aKjaer, Susanne K$$b35
000141809 7001_ $$00000-0003-0637-1534$$aModugno, Francesmary$$b36
000141809 7001_ $$aThompson, Pamela J$$b37
000141809 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b38$$udkfz
000141809 7001_ $$aHarris, Holly R$$b39
000141809 7001_ $$aSchildkraut, Joellen M$$b40
000141809 7001_ $$aLe, Nhu D$$b41
000141809 7001_ $$aWentzensen, Nico$$b42
000141809 7001_ $$00000-0002-1539-6090$$aTrabert, Britton$$b43
000141809 7001_ $$aHøgdall, Estrid$$b44
000141809 7001_ $$aHuntsman, David$$b45
000141809 7001_ $$00000-0003-4891-1199$$aPike, Malcolm C$$b46
000141809 7001_ $$aPharoah, Paul D P$$b47
000141809 7001_ $$00000-0002-8023-7846$$aPearce, Celeste Leigh$$b48
000141809 7001_ $$aMukherjee, Bhramar$$b49
000141809 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.32029$$n9$$p2192-2205$$tInternational journal of cancer$$v144$$x0020-7136$$y2019
000141809 909CO $$ooai:inrepo02.dkfz.de:141809$$pVDB
000141809 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000141809 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b38$$kDKFZ
000141809 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141809 9141_ $$y2019
000141809 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141809 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141809 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141809 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141809 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000141809 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141809 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141809 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141809 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141809 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141809 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141809 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000141809 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000141809 980__ $$ajournal
000141809 980__ $$aVDB
000141809 980__ $$aI:(DE-He78)C020-20160331
000141809 980__ $$aUNRESTRICTED